Trial Profile
A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Octohydroaminoacridine succinate (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 13 Apr 2012 New trial record